Phase 2, Randomized, Double Blinded, Study of Nivolumab (BMS-936558) in Combination With Ipilimumab vs Ipilimumab Alone in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Trial Profile

Phase 2, Randomized, Double Blinded, Study of Nivolumab (BMS-936558) in Combination With Ipilimumab vs Ipilimumab Alone in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Nivolumab (Primary) ; Ipilimumab
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms CHECKMATE-069
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Results of Gastrointestinal toxicity management in patients from phase II and III trials (CheckMate 069 and CheckMate 067; n=327) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top